Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
European operations' revenue grew 58.4% to Rs 599.7 crore
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Subscribe To Our Newsletter & Stay Updated